24 min listen
Why Pharma Needs to Forge New Drug Pricing Models
FromThe Bio Report
ratings:
Length:
29 minutes
Released:
Apr 7, 2016
Format:
Podcast episode
Description
As pricing pressure grow on the pharmaceutical industry, a recent article in Invivo argues that drugmakers must look to a variety of new pricing models built around collaborations with payers and providers. Such an approach, the authors argue, would minimize conflicts between stakeholders, close the information gap about the real-world value of new drugs, and allow for a more evidence-based approach to pricing. We spoke to Susan Garfield, a principal in EY's Life Sciences Advisory Services practice and co-author of the Invivo article, about the need for new approaches to pricing, why the existing unit price approach is too one-dimensional, and what’s at stake for the industry if it fails to innovate new models.
Released:
Apr 7, 2016
Format:
Podcast episode
Titles in the series (100)
Biotech Investors Turn Their Eyes to Policy Matters: Wall Street doesn’t like uncertainty and there are a number of policy issues now brewing that threaten to create some uncertainty for the biotechnology industry. As the BIO Investor Forum kicks off in San Francisco October 20 and 21, bringing togethe... by The Bio Report